Theranexus : Franck Mouthon détaille les résultats de phase II dans Parkinson

from Le Journal des Biotechs · host BOURSORAMA

Dans le cadre du Journal des biotechs, Franck Mouthon, PDG de Theranexus détaille les résultats de l'étude de phase II de son produit THN 102 dans la somnolence diurne excessive liée à la maladie de Parkinson.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Episode metadata supplied by the publisher feed · Published Apr 1, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

Theranexus : Franck Mouthon détaille les résultats de phase II dans Parkinson

0:00 13:51

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Le Journal des Biotechs?

This episode is 13 minutes long.

When was this Le Journal des Biotechs episode published?

This episode was published on April 1, 2020.

Can I download this Le Journal des Biotechs episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!